GlassScriptPhysician profile
Nazret Harris
NPI 1821606575
$2,812.90
in general payments reported to CMS, 2019-2025
14 companies · $1,087 in 2025
The $1,087 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $292 · 2023: $534 · 2024: $900 · 2025: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,321 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.97 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $671.49 | 2024-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $434.02 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $368.77 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $298.99 | 2022-2024 | Cequa |
| Alcon Vision LLC | $288.44 | 2022-2025 | Total30, Precision 1, Tryptyr |
| Bausch & Lomb Americas INC. | $251.90 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Harrow Eye, LLC | $155.49 | 2024-2025 | Vevye |
| Dompe US, INC. | $90.91 | 2024-2025 | Oxervate |
| Coopervision INC. | $86.38 | 2022-2023 | Myday Contact Lens |
| Abbvie INC. | $76.09 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $42.23 | 2022-2023 | |
| Amgen INC. | $19.74 | 2025 | Tepezza |
| New World Medical,INC. | $14.69 | 2022 | |
| Tearlab Corp | $13.76 | 2024 | Scoutpro Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nazret Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.